cyclopentane has been researched along with zanamivir in 89 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (21.35) | 29.6817 |
| 2010's | 69 (77.53) | 24.3611 |
| 2020's | 1 (1.12) | 2.80 |
| Authors | Studies |
|---|---|
| Ananth, SL; Andries, K; Babu, YS; Bantia, S; Chand, P; Dehghani, A; El-Kattan, Y; Horn, LL; Hutchison, TL; Kellog, DL; Kotian, PL; Lin, T; Montgomery, JA; Parker, CD | 1 |
| Bush, K; Goloubeva, OG; Govorkova, EA; Leneva, IA; Webster, RG | 1 |
| Gubareva, LV; Hayden, FG; Webster, RG | 2 |
| Colman, PM; Fernley, RT; McDonald, M; McKimm-Breshkin, JL; Smith, BJ; Varghese, JN | 1 |
| Boivin, G; Goyette, N | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Komadina, N; McDonald, M; McKimm-Breschkin, JL | 1 |
| Abed, Y; Boivin, G; Goyette, N | 1 |
| Babu, YS; Bantia, S; Chand, P; El-Kattan, Y; Kotian, PL; Lin, TH | 1 |
| Barr, IG; Hampson, AW; Hurt, AC; Iannello, P; Jachno, K; Komadina, N; McKimm-Breschkin, JL | 1 |
| Abed, Y; Baz, M; Boivin, G; McDonald, J | 1 |
| Barr, IG; Brown, L; Hurt, AC; Komadina, N; Selleck, P; Shaw, R | 1 |
| Abed, Y; Baz, M; Boivin, G | 2 |
| Reece, PA | 2 |
| Aruksakunwong, O; Decha, P; Hannongbua, S; Intharathep, P; Malaisree, M; Rungrotmongkol, T | 1 |
| Hayden, F | 1 |
| Barr, IG; Besselaar, TG; Birch, C; Buchy, P; Chittaganpitch, M; Chiu, SC; D'Souza, H; Deng, YM; Dwyer, D; Ernest, J; Guigon, A; Harrower, B; Hurt, AC; Iannello, P; Kei, IP; Kelso, A; Kok, T; Komadina, N; Lin, C; McPhie, K; Mohd, A; Olveda, R; Panayotou, T; Rawlinson, W; Scott, L; Shaw, R; Smith, D | 1 |
| Bren, U; Frecer, V; Rungrotmongkol, T; Stanislav, M; Udommaneethanakit, T | 1 |
| Deyde, VM; Garten, RJ; Gubareva, LV; Klimov, AI; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Xu, X | 1 |
| Davey, RT; Fang, F; Moss, RB; Steigbigel, RT | 1 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| DeLiberto, T; DuBois, RM; Govorkova, EA; Gramer, MR; Krauss, S; Negovetich, NJ; Senne, DA; Stallknecht, DE; Stoner, TD; Swafford, S; Webster, RG | 1 |
| Barrett, S; McKimm-Breschkin, JL; Newman, J; Oakley, AJ; Peat, TS; Saito, T; Streltsov, VA; Tashiro, M; Waddington, L | 1 |
| Ishii, H; Kadota, J; Tokimatsu, I; Yoshioka, D | 1 |
| Choi, SH; Hong, EH; Kim, MN; Kim, MS; Kim, SH; Kim, YS; Lee, JH; Lee, SO; Park, KH; Woo, JH; Yi, H | 1 |
| Abed, Y; Boivin, G; Bouhy, X; Pizzorno, A | 1 |
| Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA | 1 |
| Adams, JR; Brown, AN; Drusano, GL; Kulawy, R; McSharry, JJ; Weng, Q | 1 |
| Li, JF; Shen, JS; Xiong, RS; Zhang, Q; Zhao, QJ | 1 |
| Finelli, L; Fry, AM; Pérez, A | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Schmidt, PM | 1 |
| Boulanger, MJ; Brant, MG; Bromba, CM; Chan, T; Lunke, MD; Mason, JW; Petric, M; Wulff, JE | 1 |
| Palmer, R | 1 |
| Abed, Y; Beaulieu, E; Boivin, G; Bouhy, X; Mallett, C; Pizzorno, A; Russell, R | 1 |
| Ikematsu, H; Kashiwagi, S; Kawai, N | 1 |
| Bastien, N; Beniprashad, M; Chong-King, E; Gubbay, JB; Higgins, RR; Li, Y; Low, DE | 1 |
| Barrett, S; McKimm-Breschkin, JL; Mohr, PG; Rootes, C; Streltsov, VA | 1 |
| Dapat, C; Dapat, IC; Kawashima, T; Kondo, H; Saito, K; Saito, R; Sato, I; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Feng, E; Hilgenfeld, R; Jiang, H; Li, J; Liu, H; Wang, J; Ye, D; Zhang, D; Zhao, F; Zheng, M | 1 |
| Sato, R | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M | 1 |
| Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X | 1 |
| Barrett, S; Jachno, K; McDonald, M; McKimm-Breschkin, JL; Mohr, PG; Saito, T; Tashiro, M; Williams, J | 1 |
| Baranovich, T; Dapat, C; Dapat, IC; Kondo, H; Saito, K; Saito, R; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Cheung, PP; Choy, KT; Guan, Y; McKimm-Breschkin, JL; Ng, IH; Peiris, JS; Webby, RJ; Webster, RG; Wong, DD; Yen, HL; Zhou, J; Zhu, H | 1 |
| Baranovich, T; Burnham, AJ; Govorkova, EA | 1 |
| Hou, T; Li, D; Li, L; Li, Y; Pan, P | 1 |
| Gubareva, LV; Guo, Z; Levine, M; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Stevens, J; Tamura, D; Xu, X; Yang, H | 1 |
| Cao, B; Hayden, FG | 1 |
| Louie, JK; Samuel, MC; Schechter, R; Uyeki, TM; Yang, S | 1 |
| Long, B; Malaisree, M; McIntosh-Smith, S; Mulholland, AJ; Woods, CJ | 1 |
| Balish, A; Fry, AM; Garten, RJ; Gubareva, LV; Guo, Z; Mishin, VP; Sleeman, K; Stevens, J; Villanueva, J | 1 |
| Kwoh, CK; Ouyang, X; Tran-To Su, C; Zheng, J | 1 |
| Barr, IG; Hurt, AC; Kelso, A; Kwok, S; Leang, SK; Maurer-Stroh, S; Sullivan, SG | 1 |
| Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T | 1 |
| Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R | 1 |
| Barrett, S; McKimm-Breschkin, JL | 1 |
| Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W | 1 |
| Bastien, N; Eshaghi, A; Gubbay, JB; Higgins, RR; Li, A; Li, Y; Rosenfeld, P; Rotstein, C; Savchenko, A; Shalhoub, S; Stogios, PJ | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 2 |
| Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H | 1 |
| Baek, YH; Choi, YK; Kim, EH; Kim, MH; Kim, S; Kim, YI; Kwon, HI; Lee, EY; Lim, GJ; Park, KJ; Park, SJ; Pascua, PN; Song, MS; Webby, RJ; Yoon, SW | 1 |
| Cao, B; Chan, PK; Cheung, CS; Gu, L; Hui, DS; Kyaw, WM; Lee, N; Leo, YS; Li, H; Liu, Y; Liu, Z; Qu, J; Tam, WW; Uyeki, TM; Yung, IM | 1 |
| Ison, MG | 1 |
| Bahl, J; Baranovich, T; Culhane, M; Darnell, D; Govorkova, EA; Kaplan, BS; Lowe, JF; Marathe, BM; Stigger-Rosser, E; Webby, RJ | 1 |
| Besselaar, T; Daniels, RS; Fry, A; Gregory, V; Gubareva, L; Huang, W; Hurt, AC; Lackenby, A; Leang, SK; Lo, J; Mak, GC; Meijer, A; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Zhang, W | 1 |
| Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL | 1 |
| Azuma, T; Inoyama, T; Ishiuchi, H; Mino, Y; Sato, T; Tanaka, H; Teranishi, Y; Yamaoka, M; Yamashita, N | 1 |
| Batool, S; Kamal, MA; Kamal, W; Mushtaq, G | 1 |
| Du, J; Huang, F; Jiang, C; Jin, N; Ju, X; Li, D; Li, N; Li, X; Liang, Z; Liu, K; Liu, Q; Lu, H; Sheng, M; Tian, M; Yan, Y; Yang, P; Zhang, J; Zhang, L; Zhang, Y; Zhao, Y; Zhong, Y; Zhou, H; Zou, Z | 1 |
| Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY | 1 |
| Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y | 1 |
| Azuma, T; Hisamatsu, K; Hosomaru, K; Ishida, M; Kunitou, M; Mikata, S; Mino, Y; Otomo, K; Shimizu, M; Yunoki, A | 1 |
| Ariza-Heredia, EJ; Chemaly, RF; Shahani, L | 1 |
| Koyfman, A; Long, B; Simon, E | 1 |
| Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W | 1 |
| Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H | 1 |
| Ahn, SJ; Baek, YH; Chae, HB; Choi, WS; Choi, YK; Govorkova, EA; Hwang, J; Jeong, JH; Kim, CJ; Kim, MH; Kwon, HI; Kwon, JJ; Lloren, KKS; Song, MS; Webby, RJ | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T | 1 |
| Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M | 1 |
| Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H | 1 |
| Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N | 1 |
| Butler, J; Farrukee, R; Hurt, AC; Reading, PC | 1 |
| Donaldson, EF; Donnelly, RP; Ilyushina, NA; Ince, WL; Komatsu, TE; Lee, N; O'Rear, JJ | 1 |
| Mikurova, AV; Skvortsov, VS | 1 |
| Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
13 review(s) available for cyclopentane and zanamivir
| Article | Year |
|---|---|
Neuraminidase inhibitor resistance in influenza viruses.
Topics: Acids, Carbocyclic; Adult; Animals; Antiviral Agents; Catalytic Domain; Child; Clinical Trials as Topic; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Seasons; Sentinel Surveillance; Viral Proteins; Virulence; Zanamivir | 2007 |
Developing new antiviral agents for influenza treatment: what does the future hold?
Topics: Acids, Carbocyclic; Amides; Animals; Antiviral Agents; Cyclopentanes; Drug Discovery; Drug Resistance, Viral; Drug Therapy, Combination; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Neuraminidase; Pyrazines; Recombinant Fusion Proteins; Zanamivir | 2009 |
Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Models, Biological; Oseltamivir; Recombinant Fusion Proteins; Zanamivir | 2010 |
[Current anti-influenza virus chemotherapy].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Drug Utilization; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Japan; Oseltamivir; Pandemics; Zanamivir | 2010 |
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir | 2010 |
[Research progress of anti-influenza virus agents].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Guanidines; Humans; Indoles; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrrolidines; Rimantadine; Structure-Activity Relationship; Viral Matrix Proteins; Zanamivir | 2010 |
Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Benzoic Acid; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Models, Molecular; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Zanamivir | 2012 |
[Drug resistance of influenza viruses].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2012 |
Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Optimizing antiviral therapy for influenza: understanding the evidence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2015 |
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir | 2015 |
Antiviral therapy for respiratory viral infections in immunocompromised patients.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Coronavirus Infections; Cyclopentanes; Guanidines; Humans; Immunocompromised Host; Influenza, Human; Oseltamivir; Palivizumab; Paramyxoviridae Infections; Picornaviridae Infections; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin; Zanamivir | 2017 |
Clinical Mimics: An Emergency Medicine-Focused Review of Influenza Mimics.
Topics: Acids, Carbocyclic; Aged; Aged, 80 and over; Antiviral Agents; Child, Preschool; Cyclopentanes; Emergency Medicine; Guanidines; Humans; Infant; Influenza, Human; Middle Aged; Oseltamivir; Risk Factors; United States; Zanamivir | 2017 |
4 trial(s) available for cyclopentane and zanamivir
| Article | Year |
|---|---|
Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Treatment Outcome; Zanamivir | 2012 |
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir | 2013 |
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2017 |
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2018 |
72 other study(ies) available for cyclopentane and zanamivir
| Article | Year |
|---|---|
Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Species Specificity; Survival Analysis; Time Factors; Zanamivir | 2001 |
Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Body Weight; Brain; Cyclopentanes; Disease Models, Animal; Dogs; Female; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H9N2 Subtype; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Virus Replication; Zanamivir | 2001 |
Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.
Topics: Acetamides; Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Edetic Acid; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Microbial; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pyrans; Sialic Acids; Substrate Specificity; Zanamivir | 2001 |
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Alphainfluenzavirus; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Pyrans; Sialic Acids; Zanamivir | 2002 |
Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.
Topics: Acetamides; Acids, Carbocyclic; Canada; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fluorometry; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Luminescent Measurements; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2002 |
Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza B virus; Luminescent Measurements; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2004 |
A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Topics: Acetamides; Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Mutation; Neuraminidase; Oseltamivir; Pyrans; Recombination, Genetic; Sialic Acids; Zanamivir | 2004 |
Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo.
Topics: Acetamides; Acids, Carbocyclic; Administration, Intranasal; Administration, Oral; Animals; Antiviral Agents; Cyclopentanes; Dose-Response Relationship, Drug; Guanidines; Mice; Orthomyxoviridae; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Survival Rate; Treatment Outcome; Zanamivir | 2005 |
Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Topics: Acetamides; Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Baculoviridae; Base Sequence; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Neuraminidase; Oseltamivir; Pyrans; Recombinant Proteins; Sialic Acids; Zanamivir | 2006 |
Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Cyclopentanes; Drug Resistance, Multiple; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H3N2 Subtype; Mutation; Oseltamivir; Zanamivir | 2006 |
Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.
Topics: Acids, Carbocyclic; Amantadine; Animals; Antiviral Agents; Base Sequence; Birds; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2007 |
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Influenza A Virus, H1N1 Subtype; Mutation; Mutation, Missense; Neuraminidase; Oseltamivir; Selection, Genetic; Sequence Deletion; Viral Proteins; Zanamivir | 2007 |
Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Multiple, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Male; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2006 |
Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1.
Topics: Acids, Carbocyclic; Algorithms; Antiviral Agents; Binding Sites; Catalysis; Computer Simulation; Cyclopentanes; Databases, Protein; Guanidines; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Conformation; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Pressure; Protein Binding; Protein Structure, Secondary; Static Electricity; Temperature; Thermodynamics; Time Factors; Water; Zanamivir | 2008 |
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Asia, Southeastern; Cluster Analysis; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Oseltamivir; Phylogeny; RNA, Viral; Sequence Analysis, DNA; Sequence Homology; South Africa; Viral Proteins; Zanamivir | 2009 |
Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Drug Design; Enzyme Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Molecular Conformation; Molecular Dynamics Simulation; Neuraminidase; Organophosphonates; Oseltamivir; Time Factors; Zanamivir | 2009 |
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Sequence Analysis, DNA; Viral Proteins; Zanamivir | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Birds; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza in Birds; Influenza, Human; Models, Molecular; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Protein Conformation; Species Specificity; Swine; Swine Diseases; Viral Proteins; Zanamivir | 2010 |
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hydrogen Bonding; Influenza B virus; Models, Molecular; Molecular Structure; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2010 |
Successful salvage therapy with inhaled zanamivir in a patient with peramivir-resistant pandemic influenza A (H1N1) 2009 virus.
Topics: Acids, Carbocyclic; Administration, Inhalation; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Multiple Myeloma; Salvage Therapy; Treatment Outcome; Virus Shedding; Zanamivir | 2011 |
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrrolidines; Recombination, Genetic; Viral Plaque Assay; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir | 2010 |
Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Influenza A Virus, H1N1 Subtype; Oseltamivir; Zanamivir | 2011 |
Use of intravenous neuraminidase inhibitors during the 2009 pandemic: results from population-based surveillance.
Topics: Acids, Carbocyclic; Adult; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Infusions, Intravenous; Inpatients; Middle Aged; Population Surveillance; Practice Patterns, Physicians'; United States; Zanamivir | 2011 |
Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
Topics: Acids, Carbocyclic; Binding, Competitive; Cyclopentanes; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Inhibitory Concentration 50; Kinetics; Mutation; N-Acetylneuraminic Acid; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Substrate Specificity; Time Factors; Viral Proteins; Zanamivir | 2011 |
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
Topics: Acids, Carbocyclic; Antiviral Agents; Crystallography, X-Ray; Cyclopentanes; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Neuraminidase; Protein Binding; Recombinant Proteins; Zanamivir | 2011 |
Drugs: Lines of defence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Zanamivir | 2011 |
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Ferrets; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pandemics; Reverse Genetics; Viral Proteins; Virus Replication; Zanamivir | 2012 |
In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Neuraminidase; Oseltamivir; Zanamivir | 2012 |
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Catalytic Domain; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza B virus; Influenza, Human; Male; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; Point Mutation; RNA, Viral; Sequence Analysis, DNA; Zanamivir | 2012 |
In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
Topics: Acids, Carbocyclic; Animals; Cells, Cultured; Cyclopentanes; Dogs; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Molecular Sequence Data; Mutation, Missense; Neuraminidase; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Serial Passage; Zanamivir | 2012 |
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Catalytic Domain; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza B virus; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2012 |
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir | 2013 |
Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; DNA Mutational Analysis; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Neuraminidase; Pandemics; Pyrans; Seasons; Sialic Acids; Viral Proteins; Zanamivir | 2013 |
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Coinfection; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Plaque Assay; Viral Proteins; Zanamivir | 2013 |
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H1N1 Subtype; Molecular Dynamics Simulation; Mutant Proteins; Neuraminidase; Oseltamivir; Protein Binding; Protein Conformation; Static Electricity; Thermodynamics; Viral Proteins; Zanamivir | 2013 |
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Culture Techniques; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Viral Proteins; Virus Replication; Zanamivir | 2013 |
Therapy of H7N9 pneumonia: current perspectives.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Neuraminidase; Oseltamivir; Pulmonary Ventilation; Zanamivir | 2013 |
Neuraminidase inhibitors for critically ill children with influenza.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; California; Child; Child, Preschool; Critical Care; Critical Illness; Cyclopentanes; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Hospitalization; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza, Human; Logistic Models; Multivariate Analysis; Neuraminidase; Odds Ratio; Oseltamivir; Pandemics; Population Surveillance; Treatment Outcome; Zanamivir | 2013 |
Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.
Topics: Acids, Carbocyclic; Antiviral Agents; Computational Biology; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Zanamivir | 2013 |
Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrans; Sialic Acids; United States; Virus Replication; Zanamivir | 2014 |
Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Influenza A Virus, H7N9 Subtype; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2013 |
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Asia; Cyclopentanes; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2014 |
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir | 2015 |
Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.
Topics: Acids, Carbocyclic; Cyclopentanes; Enzyme Inhibitors; Guanidines; Kinetics; Mutant Proteins; Neuraminidase; Orthomyxoviridae; Oseltamivir; Protein Binding; Viral Proteins; Zanamivir | 2014 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2014 |
Multiple influenza A (H3N2) mutations conferring resistance to neuraminidase inhibitors in a bone marrow transplant recipient.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Fatal Outcome; Female; Guanidines; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza A Virus, H3N2 Subtype; Influenza, Human; Leukemia, B-Cell; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Transplantation, Homologous; Viral Proteins; Zanamivir | 2014 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Japan; Madin Darby Canine Kidney Cells; Middle Aged; Neuraminidase; Oseltamivir; Young Adult; Zanamivir | 2015 |
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir | 2014 |
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Genomic Instability; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Kinetics; Mice; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Viral Proteins; Virulence; Virus Replication; Zanamivir | 2015 |
Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.
Topics: Acids, Carbocyclic; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Beijing; Cohort Studies; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza, Human; Male; Middle Aged; Multivariate Analysis; Neuraminidase; Oseltamivir; Pneumonia, Bacterial; Proportional Hazards Models; Prospective Studies; Protective Factors; Respiratory Insufficiency; Retrospective Studies; Risk Factors; Singapore; Superinfection; Young Adult; Zanamivir | 2015 |
Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Base Sequence; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Guanidines; Influenza A virus; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H1N2 Subtype; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Mutation, Missense; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Phenotype; Phylogeny; Swine; Swine Diseases; Time Factors; United States; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Europe; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Inhibitory Concentration 50; Japan; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Phylogeny; Pyrans; Sialic Acids; Time Factors; United States; World Health Organization; Zanamivir | 2015 |
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir | 2015 |
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cities; Cyclopentanes; Drug Residues; Environmental Monitoring; Guanidines; Japan; Limit of Detection; Oseltamivir; Ozone; Pyrans; Risk Assessment; Rivers; Sewage; Sialic Acids; Water Pollutants, Chemical; Water Purification; Zanamivir | 2015 |
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Topics: Acids, Carbocyclic; Binding Sites; Cyclopentanes; Databases, Chemical; Glycoside Hydrolase Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Ligands; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Viral Proteins; Zanamivir | 2016 |
Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture.
Topics: Acids, Carbocyclic; Cell Death; Cell Line, Tumor; Cell Membrane; Cyclopentanes; Cytosol; Enzyme Inhibitors; Epithelial Cells; Guanidines; Humans; Hydrolysis; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Lysosomal Membrane Proteins; Lysosomes; Neuraminidase; Protein Binding; Proteolysis; Respiratory Mucosa; Species Specificity; Viral Proteins; Virus Internalization; Zanamivir | 2015 |
Fate of new three anti-influenza drugs and one prodrug in the water environment.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Biodegradation, Environmental; Cyclopentanes; Environmental Monitoring; Fresh Water; Guanidines; Half-Life; Humans; Influenza, Human; Japan; Prodrugs; Pyrans; Pyrazines; Rivers; Seasons; Sewage; Sialic Acids; Water Pollutants, Chemical; Zanamivir | 2017 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir | 2017 |
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir | 2017 |
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Birds; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza in Birds; Influenza, Human; Madin Darby Canine Kidney Cells; Mutagenesis; Neuraminidase; Orthomyxoviridae; Oseltamivir; Reverse Genetics; Zanamivir | 2018 |
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2018 |
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2016 |
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Serial Passage; Sialic Acids; Species Specificity; Viral Proteins; Zanamivir | 2019 |
Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.
Topics: Acids, Carbocyclic; Antiviral Agents; Cell Line; Crystallography, X-Ray; Cyclopentanes; Drug Resistance, Viral; Epithelial Cells; Epitopes; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H1N1 Subtype; Mutant Proteins; Mutation, Missense; Neuraminidase; Oseltamivir; Protein Conformation; Selection, Genetic; Viral Proteins; Virus Replication; Zanamivir | 2019 |
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms].
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Enzyme Inhibitors; Guanidines; Influenza A virus; Influenza B virus; Neuraminidase; Oseltamivir; Viral Proteins; Zanamivir | 2019 |
Association of moderately abnormal behavior and administered neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2020 |